In the first episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through a very busy two-week period in the field, including: - Three meetings, or what I’m calling ‘Psychedelics Week’, in D.C.: FDA’s public hearing, an ibogaine-related meeting hosted by ARPA-H, and a congressional briefing
- A commentary published by top FDA staff outlining a model for psychedelic drug development
- New Zealand’s approval of two psychiatrists to prescribe MDMA
- And many other headlines, including: Definium Therapeutics’ Phase 3 LSD for generalised anxiety disorder readout, more data from Compass Pathways’ psilocybin for treatment-resistant depression program, Xylo’s neuroplastogen enters the clinic, Eli Lilly’s acquisition of AtaiBeckley closes, RFK Jr. hosts Bryan Hubbard on his podcast to talk ibogaine, and Usona Institute files a trademark on ‘Arumaya’ a potential brand name for its psilocybin candidate.
Read more: The Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.
This episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.
Send us your questions and comments at pod@psychedelicalpha.com
Read more and join our newsletter at https://psychedelicalpha.com
Follow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.
Subscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/
|